Figure 3.
![TNFR2 marker expression in CD4+ T cells in HTLV-1 ACs vs ATL patients. (A) CD4+ T-cell lymphocyte gating strategy. (B) TNFR2+CADM1+ asymptomatic HTLV-1 carriers. (C) TNFR2+CADM1+ T-cell expression among acute ATL patients. (D) Percentage of TNFR2 expression in CADM1+ (up) and CD4+ T cells (down). (E) Correlation of plasma sTNFR2 concentration and cell surface TNFR2+CADM1+ T-cell expression (n = 12 [AC, n = 6; acute ATL, n = 6]). **P < .01.](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/4/6/10.1182_bloodadvances.2019001429/3/advancesadv2019001429f3.png?Expires=1726828016&Signature=UbDqxjfss~8g3KuMqpgLvgYK9q14mOz4KFHPw3759D6UBmB8-7u0Y0uupufdrrSTN047YNE~w0PX1oHVg84JgXntdj92cQWP~QSSsyl8BYY4ND5rySaMd0VdkXTSDdhuC~1SkiuYfq99tUJ-GGdlE9Bl4BJyzdvDvypEezH9C2sFvuctiBrae0Mjri598O-bYybM2AnklvZdAp1VeJUHuiAU2pdFrWmTulwCrnTTjRcJiuk9NSxcnAJMayYdrRW72daU4FPnnDAzFpfYR9ML4MtzT73SikVG1Lof5iNAs1nMsxklUf6keeLYVT1iDeBem2EPvZthbq8tPlfF26ScEA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
TNFR2 marker expression in CD4+ T cells in HTLV-1 ACs vs ATL patients. (A) CD4+ T-cell lymphocyte gating strategy. (B) TNFR2+CADM1+ asymptomatic HTLV-1 carriers. (C) TNFR2+CADM1+ T-cell expression among acute ATL patients. (D) Percentage of TNFR2 expression in CADM1+ (up) and CD4+ T cells (down). (E) Correlation of plasma sTNFR2 concentration and cell surface TNFR2+CADM1+ T-cell expression (n = 12 [AC, n = 6; acute ATL, n = 6]). **P < .01.